Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: KDN017
MIFTS: 62

Kidney Cancer

Categories: Blood diseases, Cancer diseases, Nephrological diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Kidney Cancer

About this section

MalaCards integrated aliases for Kidney Cancer:

IMPROVED
Name: Kidney Cancer 11 41 14 75
Renal Cancer 11 75 53 14
Renal Carcinoma 5 16 71
Kidney Neoplasm 16 71
Malignant Neoplasm of Kidney Except Pelvis 11
Malignant Neoplasm of Kidney 71
Malignant Tumour of Kidney 11
Renal Cell Carcinoma 71
Kidney Neoplasms 43
Cancer, Kidney 38
Cancer, Renal 38

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:263
ICD9CM 34 189.0
MeSH 43 D007680
SNOMED-CT 68 126880001 93849006
ICD10 31 C64
UMLS 71 C0007134 C0022665 C0494158 more
Sources

Summaries for Kidney Cancer

About this section

MedlinePlus: 41 You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys. Kidney cancer becomes more likely as you age. Risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time. You may have no symptoms at first. They may appear as the cancer grows. See your health care provider if you notice: Blood in your urine A lump in your abdomen Weight loss for no reason Pain in your side that does not go away Loss of appetite Tests to diagnose kidney cancer include blood, urine, and imaging tests. You may also have a biopsy. Treatment depends on your age, your overall health and how advanced the cancer is. It might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

MalaCards based summary: Kidney Cancer, also known as renal cancer, is related to renal cell carcinoma, nonpapillary and wilms tumor 1, and has symptoms including flank pain An important gene associated with Kidney Cancer is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are miRNAs involvement in the immune response in sepsis and miRNAs involved in DNA damage response. The drugs Ropivacaine and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, brain and endothelial.

Disease Ontology: 11 A urinary system cancer that is located in the kidney.

Wikipedia 75 Kidney cancer: Kidney cancer, also known as renal cancer, is a group of cancers that starts in the kidney. Symptoms may... more...

Renal cancer: Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...
Sources

Related Diseases for Kidney Cancer

About this section

Diseases in the Kidney Cancer family:

Kidney Carcinoma in Situ

Diseases related to Kidney Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 943)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 32.1 PVT1 MIR27A MIR214 MIR210 MIR21 MIR200C
2 wilms tumor 1 32.0 MIR27A MEG3 KCNQ1OT1 H19
3 bladder cancer 30.9 RNY3 RNY1 PVT1 MIR21 MIR185 MIR17
4 thyroid carcinoma 30.7 PVT1 MALAT1 HOTAIR H19 GAS5
5 bone disease 30.7 MIR27A MIR214 MIR210 MIR21 MIR17 MIR126
6 diabetes mellitus 30.6 PVT1 MIR27A MIR210 MIR21 MIR17 MIR126
7 osteogenic sarcoma 30.6 PVT1 MEG3 MALAT1 HOTAIR HIF1A-AS2 H19
8 hypertension, essential 30.6 MIR27A MIR214 MIR210 MIR21 MIR17 MIR126
9 neuroblastoma 30.6 MIR21 MIR17 MEG3 MALAT1 HOTAIR H19
10 melanoma 30.6 PVT1 MIR27A MIR210 MIR21 MIR200C MIR185
11 aortic aneurysm, familial abdominal, 1 30.6 MIR21 MIR126 H19
12 body mass index quantitative trait locus 11 30.5 MIR27A MIR214 MIR210 MIR21 MIR17 MIR126
13 lymphatic system disease 30.4 MIR27A MIR214 MIR210 MIR21 MIR200C MIR17
14 cerebrovascular disease 30.4 MIR27A MIR210 MIR21 MIR17 MIR126 MEG3
15 osteoarthritis 30.4 MEG3 HOTAIR H19 GAS5
16 leukemia, acute myeloid 30.4 MIR27A MIR210 MIR21 MIR17 MIR126 MEG3
17 small cell cancer of the lung 30.4 MIR21 MALAT1 HOTAIR
18 type 2 diabetes mellitus 30.3 PVT1 MIR27A MIR214 MIR210 MIR21 MIR17
19 leukemia, chronic myeloid 30.3 MIR17 MIR126 MEG3 HOTAIR H19
20 lung cancer susceptibility 3 30.3 MIR27A MIR214 MIR21 MIR200C MIR17 MIR126
21 hepatocellular carcinoma 30.3 PVT1 MIR27A MIR214 MIR21 MIR200C MIR185
22 pancreatic cancer 30.3 PVT1 MIR214 MIR210 MIR21 MIR200C MIR17
23 arteries, anomalies of 30.3 MIR27A MIR214 MIR210 MIR21 MIR185 MIR17
24 ovarian epithelial cancer 30.2 MEG3 MALAT1 HOTAIR H19
25 diffuse large b-cell lymphoma 30.2 MIR214 MIR210 MIR21 MIR17 HOTAIR
26 lipoprotein quantitative trait locus 30.2 MIR27A MIR214 MIR210 MIR21 MIR17 MIR126
27 myeloma, multiple 30.2 PVT1 MIR27A MIR21 MIR17 MIR126 MEG3
28 glioblastoma 30.2 MIR210 MIR21 MIR185 MEG3 MALAT1 HOTAIR
29 microvascular complications of diabetes 3 30.2 PVT1 MIR21 MALAT1
30 esophagus squamous cell carcinoma 30.2 PVT1 MEG3 MALAT1 HOTAIR GAS5
31 thyroid cancer, nonmedullary, 1 30.2 PVT1 MEG3 MALAT1 HOTAIR H19
32 b-cell lymphoma 30.2 PVT1 MIR17 MALAT1 HOTAIR GAS5
33 pituitary adenoma 30.2 MEG3 MALAT1 HOTAIR H19
34 bladder urothelial carcinoma 30.2 PVT1 MEG3 MALAT1 HOTAIR GAS5
35 ischemia 30.1 MIR210 MIR21 MIR17 MIR126
36 laryngeal squamous cell carcinoma 30.1 MIR21 MALAT1 HOTAIR H19
37 polymyositis 30.1 MIR214 MIR210 MIR21
38 pulmonary disease, chronic obstructive 30.1 MIR21 MIR17 MIR126 MEG3
39 microvascular complications of diabetes 5 30.1 MIR27A MIR21 MIR17 MIR126
40 heart valve disease 30.1 MIR21 MIR17 MIR126
41 prostate cancer 30.1 RNY3 RNY1 PVT1 MIR27A MIR214 MIR210
42 bone resorption disease 30.1 MIR27A MIR214 MIR210 MIR17 MIR126
43 liver cirrhosis 30.1 MEG3 MALAT1 HOTAIR GAS5
44 gallbladder cancer 30.1 MIR214 MIR17 MIR126 MEG3 MALAT1 HOTAIR
45 bile duct cancer 30.1 MIR214 MIR21 MIR17 MIR126
46 larynx cancer 30.1 MIR27A MIR210 MIR21 MIR185 MIR17
47 lung squamous cell carcinoma 30.1 PVT1 MIR200C MIR185 MIR17 MIR126 MEG3
48 aortic valve disease 2 30.0 MIR21 MIR17 MIR126
49 head and neck cancer 30.0 MIR27A MIR210 MIR21 MIR185 MIR17 MIR126
50 leukemia, acute lymphoblastic 30.0 MIR27A MIR214 MIR210 MIR21 MIR17 MIR126

Graphical network of the top 20 diseases related to Kidney Cancer:



Diseases related to Kidney Cancer
Sources

Symptoms & Phenotypes for Kidney Cancer

About this section

UMLS symptoms related to Kidney Cancer:


flank pain
Sources

Drugs & Therapeutics for Kidney Cancer

About this section

Drugs for Kidney Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 457)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
2
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
3
Nicotine Approved Phase 4 54-11-5 942 89594
4
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
5
Papaverine Approved, Investigational Phase 4 61-25-6, 58-74-2 4680
6
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
8
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
9
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
10 Psychotropic Drugs Phase 4
11 Analgesics Phase 4
12 Neurotransmitter Agents Phase 4
13 Analgesics, Non-Narcotic Phase 4
14 Hypnotics and Sedatives Phase 4
15 Narcotics Phase 4
16 Mydriatics Phase 4
17 Adrenergic alpha-Agonists Phase 4
18 Adrenergic Agonists Phase 4
19 Adrenergic Agents Phase 4
20 Bronchodilator Agents Phase 4
21 Sympathomimetics Phase 4
22 Respiratory System Agents Phase 4
23 Anti-Asthmatic Agents Phase 4
24 Vasoconstrictor Agents Phase 4
25 Adrenergic beta-Agonists Phase 4
26 Central Nervous System Stimulants Phase 4
27 Cholinergic Agents Phase 4
28 Nicotinic Agonists Phase 4
29 Cytochrome P-450 Enzyme Inhibitors Phase 4
30 Antidepressive Agents Phase 4
31 Dopamine Uptake Inhibitors Phase 4
32 Phosphodiesterase Inhibitors Phase 4
33 Anesthetics, Local Phase 4
34 Analgesics, Opioid Phase 4
35 Sodium Channel Blockers Phase 4
36 Diuretics, Potassium Sparing Phase 4
37 interferons Phase 4
38 Blood Substitutes Phase 4
39 Plasma Substitutes Phase 4
40 Hydroxyethyl Starch Derivatives Phase 4
41
Minocycline Approved, Investigational Phase 3 10118-90-8, 13614-98-7 54675783 5281021
42
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
43
Promethazine Approved, Investigational Phase 3 60-87-7 4927
44
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
45
Medroxyprogesterone acetate Approved, Investigational Phase 3 520-85-4, 71-58-9 10631 6279
46
Peginterferon alfa-2a Approved, Investigational Phase 2, Phase 3 198153-51-4
47
Sulfamethoxazole Approved Phase 3 723-46-6 5329
48
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
49
Clonidine Approved Phase 2, Phase 3 4205-91-8, 4205-90-7 2803 20179
50
Thrombin Approved, Investigational Phase 3

Interventional clinical trials:

(show top 50) (show all 1793)
# Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 Immunomodulatory Effects of Volatile and Total Intravenous Anesthesia for Patients With Renal Cancer Completed NCT03514550 Phase 4 Propofol;Sevoflurane
3 Safety Study of Nivolumab for Selected Advanced Malignancies in India Completed NCT03444766 Phase 4 Nivolumab
4 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
5 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
6 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
7 Effect of Papaverine on Intraoperative Renal Artery Blood Flow Volume in Patients Undergoing Robot-assisted Partial Nephrectomy : a Randomized, Placebo-controlled Study Completed NCT04162834 Phase 4 Papaverine;Normal saline
8 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
9 A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
10 An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy Completed NCT01266837 Phase 4 Everolimus
11 An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE). Completed NCT01206764 Phase 4 RAD001
12 Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
13 A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) Completed NCT02596035 Phase 4 Nivolumab
14 A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study) Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
15 Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma or Metastatic Melanoma With Immunologic Correlative Studies Completed NCT00414765 Phase 4 Aldesleukin
16 An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
17 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Completed NCT02555748 Phase 4 Pazopanib;Sunitinib
18 Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Completed NCT02982954 Phase 4 Nivolumab;Ipilimumab
19 Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
20 A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy Recruiting NCT03824808 Phase 4 Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution;0.9% Sodium Chloride Injection
21 A Phase 4 Study of Nivolumab in Combination With Ipilimumab in Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate-or Poor-risk Factors Conducted in India Recruiting NCT04513522 Phase 4
22 Low-dose Neuroleptanalgesia Reduce the Occurrences of Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Major Surgery : a Randomized Controlled Trial Recruiting NCT05068180 Phase 4 low-dose neuroleptanalgesia;Placebo
23 Effect of Hydroxyethyl Starch on Renal Handling of Salt and Water, Blood Pressure-regulating Hormones, Proteins and Circulatory System of Patients Undergoing Kidney Removal by Keyhole Surgery Terminated NCT01486550 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
24 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Terminated NCT02570789 Phase 4 patients with sunitinib or pazopanib
25 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
26 A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
27 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor Terminated NCT02338570 Phase 4 Everolimus
28 The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Terminated NCT01413607 Phase 4
29 Nephroblastoma (Wilms Tumour) Clinical Trial And Study Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
30 Nephroblastoma Clinical Trial and Study Unknown status NCT00003804 Phase 3 vincristine sulfate
31 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
32 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium: A Multicenter, Randomized, Double-Blind Clinical Trail Unknown status NCT02928692 Phase 3 Minocycline;Placebo
33 Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
34 Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib) Unknown status NCT00869011 Phase 3
35 Phase 3 Trial of Intravenous Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes Completed NCT01606787 Phase 3 mannitol
36 Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer Completed NCT00369564 Phase 3 glutamic acid
37 Adjuvant Interleukin-2, Interferon-alpha and 5-Fluorouracil for Patients With High Risk of Relapse After Surgical Treatment for Renal Cell Carcinoma Completed NCT00053807 Phase 3 fluorouracil
38 AE-941 (NEOVASTAT) Versus Placebo in Metastatic Renal Cell Carcinoma Patients Who Are Refractory to Immunotherapy Completed NCT00005995 Phase 3 shark cartilage extract AE-941
39 A RANDOMIZED PHASE II TRIAL OF INTERFERON ALPHA-2A WITH AND WITHOUT 13-CIS RETINOIC ACID IN PATIENTS WITH PROGRESSIVE MEASURABLE METASTATIC RENAL CELL CARCINOMA. Amendment Protocol: Extension to a Randomized Phase III Trial Completed NCT00002737 Phase 3 chemotherapy;isotretinoin
40 A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250) Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
41 Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis [PERCY QUATTRO] Completed NCT00416429 Phase 3 medroxyprogesterone
42 A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER) Completed NCT00087022 Phase 3
43 Phase III Randomized Study of Intravenous Low Dose Versus Intravenous High Dose Versus Subcutaneous Interleukin-2 for Metastatic Renal Cell Carcinoma Completed NCT00018941 Phase 3
44 Phase III Randomized Trial of Interferon-Alfa2b Alone Versus Interferon-Alfa2b Plus Thalidomide in Patients With Previously Untreated Metastatic or Unresectable Renal Cell Carcinoma Completed NCT00005966 Phase 3 thalidomide
45 Cytokines in the Treatment of Metastatic Renal Cell Carcinoma (MRCC): Intravenous Interleukin and Subcutaneous Interferon-α Versus Subcutaneous Interleukin and Interferon-α for Good Prognosis Patients [PERCY DUO] Completed NCT00416871 Phase 3
46 A Randomized Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma Completed NCT00053820 Phase 3 fluorouracil
47 A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma Completed NCT00072046 Phase 3
48 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
49 NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
50 A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma Completed NCT00003126 Phase 3 Interleukin-2

Search NIH Clinical Center for Kidney Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
axitinib
cabozantinib
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
lenvatinib
Lomustine
Medroxyprogesterone
medroxyprogesterone acetate
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
sorafenib
sunitinib
sunitinib malate
temsirolimus
Thalidomide
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: kidney neoplasms

Sources

Genetic Tests for Kidney Cancer

About this section
Sources

Anatomical Context for Kidney Cancer

About this section

Organs/tissues related to Kidney Cancer:

FMA: Kidney
MalaCards : Kidney, Brain, Endothelial, Lung, T Cells, Prostate, Lymph Node
Sources

Publications for Kidney Cancer

About this section

Articles related to Kidney Cancer:

(show top 50) (show all 16627)
# Title Authors PMID Year
1
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. 62 5
24631838 2014
2
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. 62 5
24622468 2014
3
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
4
The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. 5
24121490 2013
5
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. 5
23610116 2013
6
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. 5
23213094 2013
7
Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. 62 46
19646430 2010
8
Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. 62 46
18925646 2008
9
Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. 5
18829470 2008
10
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. 5
11750879 2002
11
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. 41
36104138 2022
12
Spinal anaesthesia with clonidine: pain relief and earlier mobilisation after open nephrectomy - a randomised clinical trial. 41
36177827 2022
13
Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator. 41
36150744 2022
14
No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome. 53 62
20091131 2010
15
Multi-modal treatment for metastatic renal cancer: the role of surgery. 53 62
20364382 2010
16
Urinary biomarkers for the early diagnosis of kidney cancer. 53 62
20375178 2010
17
Screening for kidney cancer: is there a role for aquaporin-1 and adipophilin? 53 62
20435833 2010
18
The genetic basis of kidney cancer: a metabolic disease. 53 62
20448661 2010
19
Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. 53 62
20425594 2010
20
Influence of osteopontin short hairpin RNA on the proliferation and invasion of human renal cancer cells. 53 62
20155457 2010
21
Compounds in clinical Phase III and beyond. 53 62
20033382 2010
22
Molecular diagnosis and therapy of kidney cancer. 53 62
20059341 2010
23
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. 53 62
20054297 2010
24
Molecular basis for the treatment of renal cell carcinoma. 53 62
20080466 2010
25
Management of vascular endothelial growth factor and multikinase inhibitor side effects. 53 62
19948455 2009
26
In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. 53 62
19801515 2009
27
The sterol-sensing endoplasmic reticulum (ER) membrane protein TRC8 hampers ER to Golgi transport of sterol regulatory element-binding protein-2 (SREBP-2)/SREBP cleavage-activated protein and reduces SREBP-2 cleavage. 53 62
19706601 2009
28
Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. 53 62
19639177 2009
29
VHL loss causes spindle misorientation and chromosome instability. 53 62
19620968 2009
30
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. 53 62
19470762 2009
31
TGF-alpha as a candidate tumor antigen for renal cell carcinomas. 53 62
19052740 2009
32
Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2? 53 62
19663736 2009
33
P-glycoprotein activity in renal clear cell carcinoma. 53 62
18440836 2009
34
[Case of drug-induced colitis like ulcerative colitis during IL-2 therapy for multiple bone metastasis after operation of kidney cancer]. 53 62
19663247 2009
35
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. 53 62
19451442 2009
36
Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. 53 62
19675744 2009
37
Targeting the Met signaling pathway in renal cancer. 53 62
19496715 2009
38
The role of antiangiogenesis therapy: bevacizumab and beyond. 53 62
19531449 2009
39
Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. 53 62
19402056 2009
40
Hereditary kidney cancer: unique opportunity for disease-based therapy. 53 62
19402075 2009
41
Proepithelin is an autocrine growth factor for bladder cancer. 53 62
19237611 2009
42
High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer. 53 62
19409039 2009
43
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. 53 62
19318488 2009
44
mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option. 53 62
19236264 2009
45
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. 53 62
19238017 2009
46
[Hereditary renal cancer]. 53 62
19418834 2009
47
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. 53 62
19165638 2009
48
[IL-2 bronchoscopic istillation and immune cell activation: preliminary results of the BRIIL-2 study for treatment of pulmonary metastasis from renal cancer and melanoma]. 53 62
19452104 2009
49
Implication of bevacizumab in fatal arterial thromboembolic incidents. 53 62
19365880 2009
50
Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. 53 62
19891126 2008
Sources

Variations for Kidney Cancer

About this section

ClinVar genetic disease variations for Kidney Cancer:

IMPROVED
5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MET NM_000245.4(MET):c.3688T>C (p.Tyr1230His) SNV Likely Pathogenic
 194929 rs121913247 GRCh37: 7:116423413-116423413
GRCh38: 7:116783359-116783359
2 MET NM_000245.4(MET):c.3749T>C (p.Met1250Thr) SNV Likely Pathogenic
 376126 rs121913245 GRCh37: 7:116423474-116423474
GRCh38: 7:116783420-116783420
3 MET NM_000245.4(MET):c.3280C>T (p.His1094Tyr) SNV Likely Pathogenic
 376068 rs121913244 GRCh37: 7:116417463-116417463
GRCh38: 7:116777409-116777409
4 MTOR NM_004958.4(MTOR):c.7514G>C (p.Arg2505Pro) SNV Likely Pathogenic
 376127 rs1057519777 GRCh37: 1:11169361-11169361
GRCh38: 1:11109304-11109304
5 MTOR NM_004958.4(MTOR):c.6667C>A (p.Gln2223Lys) SNV Likely Pathogenic
 376128 rs1057519778 GRCh37: 1:11182179-11182179
GRCh38: 1:11122122-11122122
6 MET NM_000245.4(MET):c.3689A>G (p.Tyr1230Cys) SNV Likely Pathogenic
 13885 rs121913246 GRCh37: 7:116423414-116423414
GRCh38: 7:116783360-116783360
7 MTOR NM_004958.4(MTOR):c.4379T>C (p.Leu1460Pro) SNV Likely Pathogenic
 376130 rs1057519779 GRCh37: 1:11217299-11217299
GRCh38: 1:11157242-11157242
8 MET NM_000245.4(MET):c.3281A>G (p.His1094Arg) SNV Likely Pathogenic
 13887 rs121913243 GRCh37: 7:116417464-116417464
GRCh38: 7:116777410-116777410
9 MTOR NM_004958.4(MTOR):c.6644C>A (p.Ser2215Tyr) SNV Likely Pathogenic
 376129 rs587777894 GRCh37: 1:11184573-11184573
GRCh38: 1:11124516-11124516

Cosmic variations for Kidney Cancer:

8 (show top 50) (show all 852)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88297043 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 16
2 COSM90657935 VHL kidney,NS,carcinoma,renal cell c.362G>T p.C121F 3:10149808-10149808 16
3 COSM85360217 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176= 3:124737785-124737785 16
4 COSM93517001 TRIO kidney,NS,carcinoma,renal cell c.1505A>G p.N502S 5:14508136-14508136 16
5 COSM143919608 TRIO kidney,NS,carcinoma,renal cell c.706-1273A>G p.? 5:14508136-14508136 16
6 COSM89062698 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 16
7 COSM90865192 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 2:7020581-7020581 16
8 COSM94389604 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 16
9 COSM94442225 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 16
10 COSM94492333 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 16
11 COSM92824042 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 16
12 COSM94232725 RABGAP1 kidney,NS,carcinoma,renal cell c.1749T>A p.H583Q 9:123020414-123020414 16
13 COSM106795558 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 16
14 COSM130825760 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 16
15 COSM94057597 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 16
16 COSM126664114 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 16
17 COSM131800227 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 16
18 COSM114430588 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 16
19 COSM100863866 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 11:118497991-118497991 16
20 COSM129143197 KMT2A kidney,NS,carcinoma,renal cell c.5720C>T p.A1907V 11:118497991-118497991 16
21 COSM144159091 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 6:33682621-33682621 16
22 COSM96915510 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 6:33682621-33682621 16
23 COSM86472399 H2BC1 kidney,NS,carcinoma,renal cell c.239C>A p.S80* 6:25727147-25727147 16
24 COSM146087884 DOCK1 kidney,NS,carcinoma,renal cell c.1369G>T p.D457Y 10:127023241-127023241 16
25 COSM88845534 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 10:127023241-127023241 16
26 COSM102230151 DDX19B kidney,NS,carcinoma,renal cell c.216G>A p.V72= 16:70325624-70325624 16
27 COSM137305195 DDX19B kidney,NS,carcinoma,renal cell c.558G>A p.V186= 16:70325624-70325624 16
28 COSM137613380 DDX19B kidney,NS,carcinoma,renal cell c.216G>A p.V72= 16:70325624-70325624 16
29 COSM136951592 DDX19B kidney,NS,carcinoma,renal cell c.216G>A p.V72= 16:70325624-70325624 16
30 COSM88298617 DDX19B kidney,NS,carcinoma,renal cell c.543G>A p.V181= 16:70325624-70325624 16
31 COSM92903161 DDX19B kidney,NS,carcinoma,renal cell c.450G>A p.V150= 16:70325624-70325624 16
32 COSM111962535 DDX19B kidney,NS,carcinoma,renal cell c.465G>A p.V155= 16:70325624-70325624 16
33 COSM125364846 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 16
34 COSM88086191 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 16
35 COSM120703070 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 16
36 COSM122317683 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 16
37 COSM95279694 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 6:44419552-44419552 16
38 COSM129930398 ARHGAP20 kidney,NS,carcinoma,renal cell c.1277A>G p.D426G 11:110586276-110586276 16
39 COSM128048829 ARHGAP20 kidney,NS,carcinoma,renal cell c.1247A>G p.D416G 11:110586276-110586276 16
40 COSM130426538 ARHGAP20 kidney,NS,carcinoma,renal cell c.-17A>G p.? 11:110586276-110586276 16
41 COSM127507491 ARHGAP20 kidney,NS,carcinoma,renal cell c.1286A>G p.D429G 11:110586276-110586276 16
42 COSM85547904 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 11:110586276-110586276 16
43 COSM128420528 ARHGAP20 kidney,NS,carcinoma,renal cell c.1247A>G p.D416G 11:110586276-110586276 16
44 COSM111167644 kidney,NS,carcinoma,renal cell c.160+10669G>A p.? 16:70325624-70325624 16
45 COSM108082894 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 14
46 COSM92179769 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 14
47 COSM94289415 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 14
48 COSM90652475 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.245G>C p.R82P 3:10142092-10142092 14
49 COSM90649111 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-3275A>T p.? 3:10146512-10146512 14
50 COSM88289113 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-2A>T p.? 3:10146512-10146512 14

Copy number variations for Kidney Cancer from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 166351 3 10158318 10168746 Mutations VHL Renal cancer
Sources

Expression for Kidney Cancer

About this section
Search GEO for disease gene expression data for Kidney Cancer.
Sources

Pathways for Kidney Cancer

About this section


Pathways directly related to Kidney Cancer:

# Pathway Source
1 Signaling by AMER1 mutants Reactome 66

Pathways related to Kidney Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
miRNAs involvement in the immune response in sepsis 74
11.12 MIR21 MIR200C MIR126
2
miRNAs involved in DNA damage response 74
11.08 MIR27A MIR210 MIR21 MIR17
3
Interactions between immune cells and microRNAs in tumor microenvironment 74
10.7 MIR27A MIR214 MIR210 MIR21 MIR200C
4
ncRNAs involved in STAT3 signaling in hepatocellular carcinoma 74
10.51 MIR21 MIR200C
Sources

GO Terms for Kidney Cancer

About this section

Cellular components related to Kidney Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.6 MIR27A MIR214 MIR210 MIR21 MIR200C MIR185
2 extracellular vesicle GO:1903561 9.43 MIR27A MIR214 MIR21 MIR185 MIR17 MIR126

Biological processes related to Kidney Cancer according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.99 MIR27A MIR214 MIR21 MIR185 MIR17
2 negative regulation of cell migration GO:0030336 9.91 MIR214 MIR21 MIR185 MIR126
3 cellular response to hypoxia GO:0071456 9.86 MALAT1 MIR126 MIR17 MIR214
4 miRNA-mediated gene silencing GO:0035195 9.86 H19 MEG3 MIR126 MIR17 MIR185 MIR200C
5 negative regulation of BMP signaling pathway GO:0030514 9.79 MIR214 MIR210 MIR17
6 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.71 MIR21 MIR17 H19
7 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.71 MIR27A MIR214 MIR21 MIR17
8 positive regulation of vascular endothelial cell proliferation GO:1905564 9.7 MIR27A MIR21 MIR126
9 miRNA-mediated gene silencing by mRNA destabilization GO:0035279 9.65 MIR27A MIR214 MIR210
10 positive regulation of osteoblast differentiation GO:0045669 9.65 MIR27A MIR210 MIR21 MIR200C HIF1A-AS2
11 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.63 MIR27A MIR21 MIR126
12 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.61 MIR17 MIR185 MIR27A
13 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.6 MIR27A MIR185
14 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.58 MIR27A MIR21
15 positive regulation of miRNA catabolic process GO:2000627 9.58 KCNQ1OT1 GAS5
16 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.57 MIR214 MIR17
17 positive regulation of metalloendopeptidase activity GO:1904685 9.55 MIR21 MIR17
18 negative regulation of miRNA-mediated gene silencing GO:0060965 9.54 PVT1 KCNQ1OT1 HIF1A-AS2
19 negative regulation of superoxide dismutase activity GO:1901670 9.51 MIR21 H19
20 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.5 MIR210 MIR21 MIR17
21 lncRNA-mediated post-transcriptional gene silencing GO:0000512 9.49 KCNQ1OT1 GAS5
22 negative regulation of BMP secretion GO:2001285 9.33 MIR214 MIR210 MIR17
23 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.1 MIR27A MIR210 MIR21 MIR200C MIR17 MIR126

Molecular functions related to Kidney Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.56 MIR27A MIR214 MIR210 MIR21 MIR200C MIR185
2 miRNA binding GO:0035198 9.46 PVT1 KCNQ1OT1 HIF1A-AS2 GAS5
3 miRNA inhibitor activity GO:0140869 9.26 KCNQ1OT1 GAS5
4 mRNA base-pairing translational repressor activity GO:1903231 9.23 MIR27A MIR214 MIR210 MIR21 MIR200C MIR185
Sources

Sources for Kidney Cancer

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....